Search

Your search keyword '"Pordy, Robert"' showing total 106 results

Search Constraints

Start Over You searched for: Author "Pordy, Robert" Remove constraint Author: "Pordy, Robert" Database Unpaywall Remove constraint Database: Unpaywall
106 results on '"Pordy, Robert"'

Search Results

1. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy

3. Safety Of The Pcsk9 Inhibitor Alirocumab: insights From 47,296 Patient-Years Of Observation

4. Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: ODYSSEY OUTCOMES

6. Abstract 16672: Effects of Evinacumab on Atherogenic Lipoproteins in Children and Adolescents From Ages 5 to 17 Years With Homozygous Familial Hypercholesterolemia

7. Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis

8. The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

10. Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome

11. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

12. LIPOPROTEIN(A) AND CARDIOVASCULAR OUTCOMES IN WOMEN AND MEN AFTER AN ACUTE CORONARY SYNDROME: A POST HOC ODYSSEY OUTCOMES TRIAL ANALYSIS

13. SHORT-DURATION, VERY HIGH-INTENSITY LIPID-LOWERING THERAPY RESULTS IN PROLONGED REDUCTION OF CARDIOVASCULAR EVENTS FOLLOWING ACUTE CORONARY SYNDROME

15. Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES

16. Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes

17. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

18. Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial

20. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial

23. Abstract 12066: The Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

24. Abstract 12756: Long-Term Efficacy and Safety of Evinacumab in Adult and Adolescent Patients With Homozygous Familial Hypercholesterolemia

26. Abstract 12027: Low-Density Lipoprotein Cholesterol in Patients With Homozygous Familial Hypercholesterolemia Who Participated in Sequential Studies of Alirocumab and Evinacumab

27. The effect of evinacumab on LDL-C goal attainment in patients with homozygous familial hypercholesterolemia

30. EFFECTS OF ALIROCUMAB ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH PREVIOUS MYOCARDIAL INFARCTION: SUBANALYSIS FROM THE ODYSSEY OUTCOMES TRIAL

31. EFFECTS OF ALIROCUMAB IN PATIENTS WITH RECENT ACS AND A HISTORY OF HEART FAILURE: AN ANALYSIS OF THE ODYSSEY OUTCOMES TRIAL

32. METABOLIC RISK FACTORS AND THE EFFECT OF ALIROCUMAB ON CARDIOVASCULAR EVENTS IN PATIENTS AFTER ACUTE CORONARY SYNDROME: AN ANALYSIS OF THE ODYSSEY OUTCOMES RANDOMIZED CONTROLLED TRIAL

34. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

35. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

36. Evinacumab in Patients with Refractory Hypercholesterolemia

38. Abstract 14270: The Effect of Evinacumab on Apheresis Eligibility in Patients With Homozygous Familial Hypercholesterolemia

39. Abstract 14267: Evinacumab Lowers LDL-C in Patients With Homozygous Familial Hypercholesterolemia Irrespective of Background Lipid-lowering Medication

40. Abstract 14407: The Longer-term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

41. Abstract 15281: Triglyceride Levels and Cardiovascular Outcomes After Acute Coronary Syndrome: Insights From the Odyssey Outcomes Trial

42. Evinacumab for Homozygous Familial Hypercholesterolemia

43. The Efficacy and Safety of Evinacumab in Homozygous Familial Hypercholesterolemia Patients with Little to No Low-Density Lipoprotein Receptor Activity

44. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia

46. Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes

47. ACHIEVEMENT OF NEW EUROPEAN DYSLIPIDEMIA-GUIDELINE LOW-DENSITY LIPOPROTEIN CHOLESTEROL TREATMENT GOALS AFTER ACUTE CORONARY SYNDROME: INSIGHTS FROM ODYSSEY OUTCOMES

48. ALIROCUMAB AND CARDIOVASCULAR OUTCOMES IN WOMEN AFTER AN ACUTE CORONARY SYNDROME: AN ODYSSEY OUTCOMES TRIAL ANALYSIS

49. EFFECT OF ALIROCUMAB ON FIRST AND TOTAL REVASCULARIZATIONS IN PATIENTS WITH RECENT ACUTE CORONARY SYNDROME IN THE ODYSSEY OUTCOMES TRIAL

50. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

Catalog

Books, media, physical & digital resources